FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / PLoS One / Equine pituitary pars intermedia dysfunction: Identifying re...
PloS one2021; 16(1); e0244784; doi: 10.1371/journal.pone.0244784

Equine pituitary pars intermedia dysfunction: Identifying research priorities for diagnosis, treatment and prognosis through a priority setting partnership.

Abstract: Pituitary pars intermedia dysfunction (PPID) is the most prevalent endocrine disorder of older equids. To date, key research areas likely to have the greatest impact on equine health have not been identified. In human medicine, public and patient involvement is widely used to inform research agendas. This study aimed to engage with veterinary surgeons and horse owners to identify evidence gaps ('uncertainties') and prioritise these into a list of the 10 most important PPID research questions. The James Lind Alliance (JLA) Priority Setting Partnership (PSP) Framework was adapted. Questions about the diagnosis, treatment and prognosis of PPID were gathered via an online survey targeting veterinary surgeons and horse owners with experience of PPID. Thematic analysis was used to form a longlist of collated indicative research questions (CIRQs), defined by the JLA as true 'evidence uncertainties' when not answered by a published, clinically relevant, up-to-date systematic review. In an interim prioritisation survey, questions were ranked by weighted scores creating a shortlist of 25 that were taken forward to the PSP workshop, where participants reached a consensus on the top 10. Useable responses containing ≥1 question were received from 524 respondents (92.6% owners, n = 485; 7.4% veterinary surgeons, n = 39). After screening for relevance, 1,260 individual questions were included in thematic analysis, resulting in 47 CIRQs. Interim prioritisation votes for the CIRQs were received from 360 respondents. The top 10 questions prioritised at the PSP workshop focused on long-term prognosis, diagnostic accuracy, efficacy of pergolide treatment, alternative treatment/management strategies and potential treatment options for poor responders to pergolide. The quantity of questions generated indicates an extensive number of uncertainties regarding the diagnosis, treatment and prognosis of PPID. The top 10 research questions will help to inform key areas for evidence synthesis and knowledge translation, and to direct future research into areas most important to end users involved in caring for and treating animals with PPID.
Get Full Text
Publication Date: 2021-01-04 PubMed ID: 33395695PubMed Central: PMC7781667DOI: 10.1371/journal.pone.0244784Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research study aimed to identify the top ten uncertain areas of research into the pituitary pars intermedia dysfunction (PPID), a common endocrine disorder in aged horses. The areas of uncertainty were identified through a survey involving veterinarians and horse owners who have experience with PPID. The highlighted areas could then be prioritized to help in future research.

Research Methodology

  • The framework used for this study was the James Lind Alliance (JLA) Priority Setting Partnership (PSP). This survey-based approach is designed to bring patient-centric viewpoints into consideration when setting a research agenda. The framework was adapted for use in a veterinary setting instead of its normal human medical setting.
  • Questions about diagnosing, treating, and predicting the course of PPID were collected through an online survey. The respondents of this survey were veterinary surgeons and horse owners who have experience dealing with PPID.
  • The responses were analyzed using a thematic approach and were formed into a long list of collated indicative research questions (CIRQs), which are defined by the JLA as true ‘evidence uncertainties’ when they cannot be answered by an existing, clinically relevant, up-to-date systematic review.
  • An interim prioritization survey was then carried out, with responses weighted according to their perceived importance. This resulted in a shortlist of 25 questions that were taken forward to a PSP workshop.
  • At this workshop, the respondents reached a consensus on the top ten questions that require further research.

Results and Implications

  • The survey received responses containing at least one question from 524 respondents, the vast majority of whom were horse owners. A total of 1,260 individual questions were submitted.
  • These questions were then analysed and grouped into 47 CIRQs. The interim prioritization survey received votes from 360 respondents.
  • At the PSP workshop, the top ten questions centred around long-term prognosis, diagnostic accuracy, efficacy of pergolide treatment (a common drug used to treat PPID), alternative treatment strategies and potential treatments for those horses that did not respond well to pergolide.
  • The large number of questions generated points to a great deal of uncertainty surrounding the diagnosis, treatment, and prognosis of PPID.
  • The top ten questions identified in this study will aid future research efforts into PPID by highlighting the areas that have the greatest potential impact on equine health. This should lead to better evidence synthesis and knowledge translation in the field, ultimately benefiting the animals affected by PPID and those involved in their care.

Cite This Article

APA
Tatum RC, McGowan CM, Dean RS, Ireland JL. (2021). Equine pituitary pars intermedia dysfunction: Identifying research priorities for diagnosis, treatment and prognosis through a priority setting partnership. PLoS One, 16(1), e0244784. https://doi.org/10.1371/journal.pone.0244784

Publication

PloS one
ISSN: 1932-6203
NlmUniqueID: 101285081
Country: United States
Language: English
Volume: 16
Issue: 1
Pages: e0244784
PII: e0244784

Researcher Affiliations

Tatum, Rebecca C
  • Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom.
  • Centre for Preventive Medicine, Animal Health Trust, Newmarket, Suffolk, United Kingdom.
McGowan, Cathy M
  • Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom.
Dean, Rachel S
  • Centre for Evidence-based Veterinary Medicine, University of Nottingham, Sutton Bonington, Leicestershire, United Kingdom.
Ireland, Joanne L
  • Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom.

MeSH Terms

  • Animals
  • Biomedical Research / trends
  • Consensus
  • Health Priorities / statistics & numerical data
  • Horse Diseases / diagnosis
  • Horse Diseases / physiopathology
  • Horses
  • Patient Participation
  • Pituitary Diseases / diagnosis
  • Pituitary Gland, Intermediate / metabolism
  • Pituitary Gland, Intermediate / physiopathology
  • Prognosis
  • Research / trends
  • Stakeholder Participation
  • Surveys and Questionnaires
  • Veterinarians

Conflict of Interest Statement

As a collaborator Boehringer Ingelheim Animal Health UK Limited part funded this study, however, their only involvement in the priority setting partnership was to help disseminate the initial questionnaire to relevant participants. Both JI and CM have previously received funding for other specific equine endocrinology research projects from Boehringer Ingelheim Animal Health. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The authors have no financial or personal relationships with other people or organisations that could inappropriately influence or bias the content of the paper.

References

This article includes 59 references
  1. McFarlane D, Cribb AE. Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses.. Am J Vet Res 2005 Dec;66(12):2065-72.
    doi: 10.2460/ajvr.2005.66.2065pubmed: 16379648google scholar: lookup
  2. McGowan TW, Pinchbeck GP, McGowan CM. Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses.. Equine Vet J 2013 Jan;45(1):74-9.
    doi: 10.1111/j.2042-3306.2012.00578.xpubmed: 22594955google scholar: lookup
  3. Miller MA, Pardo ID, Jackson LP, Moore GE, Sojka JE. Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction.. Vet Pathol 2008 Jan;45(1):26-38.
    doi: 10.1354/vp.45-1-26pubmed: 18192571google scholar: lookup
  4. McFarlane D. Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease.. Ageing Res Rev 2007 May;6(1):54-63.
    doi: 10.1016/j.arr.2007.02.001pubmed: 17374512google scholar: lookup
  5. McFarlane D, Miller LM, Craig LE, Dybdal NO, Habecker PL, Miller MA, Patterson JS, Cribb AE. Agreement in histologic assessments of the pituitary pars intermedia in aged horses.. Am J Vet Res 2005 Dec;66(12):2055-9.
    doi: 10.2460/ajvr.2005.66.2055pubmed: 16379646google scholar: lookup
  6. McFarlane D, Dybdal N, Donaldson MT, Miller L, Cribb AE. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction.. J Neuroendocrinol 2005 Feb;17(2):73-80.
    doi: 10.1111/j.1365-2826.2005.01277.xpubmed: 15796757google scholar: lookup
  7. Heinrichs M, Baumgärtner W, Capen CC. Immunocytochemical demonstration of proopiomelanocortin-derived peptides in pituitary adenomas of the pars intermedia in horses.. Vet Pathol 1990 Nov;27(6):419-25.
    doi: 10.1177/030098589902700606pubmed: 2177580google scholar: lookup
  8. McFarlane D. Equine pituitary pars intermedia dysfunction.. Vet Clin North Am Equine Pract 2011 Apr;27(1):93-113.
    doi: 10.1016/j.cveq.2010.12.007pubmed: 21392656google scholar: lookup
  9. Schott HC 2nd. Pituitary pars intermedia dysfunction: equine Cushing's disease.. Vet Clin North Am Equine Pract 2002 Aug;18(2):237-70.
    doi: 10.1016/s0749-0739(02)00018-4pubmed: 15635907google scholar: lookup
  10. Ireland JL, McGowan CM. Epidemiology of pituitary pars intermedia dysfunction: A systematic literature review of clinical presentation, disease prevalence and risk factors.. Vet J 2018 May;235:22-33.
    doi: 10.1016/j.tvjl.2018.03.002pubmed: 29704935google scholar: lookup
  11. Frank N, Andrews FM, Sommardahl CS, Eiler H, Rohrbach BW, Donnell RL. Evaluation of the combined dexamethasone suppression/ thyrotropin-releasing hormone stimulation test for detection of pars intermedia pituitary adenomas in horses.. J Vet Intern Med 2006 Jul-Aug;20(4):987-93.
    doi: 10.1892/0891-6640(2006)20[987:eotcdt]2.0.co;2pubmed: 16955827google scholar: lookup
  12. Mc Gowan TW, Pinchbeck GP, Mc Gowan CM. Evaluation of basal plasma α-melanocyte-stimulating hormone and adrenocorticotrophic hormone concentrations for the diagnosis of pituitary pars intermedia dysfunction from a population of aged horses.. Equine Vet J 2013 Jan;45(1):66-73.
    doi: 10.1111/j.2042-3306.2012.00575.xpubmed: 22563728google scholar: lookup
  13. Muñoz MC, Doreste F, Ferrer O, González J, Montoya JA. Pergolide treatment for Cushing's syndrome in a horse.. Vet Rec 1996 Jul 13;139(2):41-3.
    doi: 10.1136/vr.139.2.41pubmed: 8839490google scholar: lookup
  14. . Freedom of Information Summary Corrected Original New Animal Drug Application Prascend Tablets Pergolide Mesylate. NADA 2011 nSeptember [cited 2017 May 03]; 141–331.
  15. Sgorbini M, Panzani D, Maccheroni M, Corazza M. Equine cushing-like syndrome: diagnosis and therapy in two cases.. Vet Res Commun 2004 Aug;28 Suppl 1:377-80.
    pubmed: 15373001doi: 10.1023/b:verc.0000045368.38959.8bgoogle scholar: lookup
  16. Aleman M, Watson JL, Williams DC, LeCouteur RA, Nieto JE, Shelton GD. Myopathy in horses with pituitary pars intermedia dysfunction (Cushing's disease).. Neuromuscul Disord 2006 Nov;16(11):737-44.
    doi: 10.1016/j.nmd.2006.07.019pubmed: 17005399google scholar: lookup
  17. Spelta CW, Axon JE. Case series of equine pituitary pars intermedia dysfunction in a tropical climate.. Aust Vet J 2012 Nov;90(11):451-6.
    pubmed: 23106327doi: 10.1111/j.1751-0813.2012.00997.xgoogle scholar: lookup
  18. Rohrbach BW, Stafford JR, Clermont RS, Reed SM, Schott HC 2nd, Andrews FM. Diagnostic frequency, response to therapy, and long-term prognosis among horses and ponies with pituitary par intermedia dysfunction, 1993-2004.. J Vet Intern Med 2012 Jul-Aug;26(4):1027-34.
    pubmed: 22524260doi: 10.1111/j.1939-1676.2012.00932.xgoogle scholar: lookup
  19. Peters DF, Erfle JB, Slobojan GT. Low-dose pergolide mesylate treatment for equine hypophyseal adenomas. Proc Am Assoc Equine Pr 1995; 41: 154–155.
  20. Tallon D, Chard J, Dieppe P. Relation between agendas of the research community and the research consumer.. Lancet 2000 Jun 10;355(9220):2037-40.
    doi: 10.1016/S0140-6736(00)02351-5pubmed: 10885355google scholar: lookup
  21. Oliver S, Milne R, Bradburn JD, Buchanan P, Kerridge L, Walley T, Gabbay J. Investigating consumer perspectives on evaluating health technologies. Evaluation 2001; 7(4): 468–86.
  22. Chalmers I. What do I want from health research and researchers when I am a patient?. BMJ 1995 May 20;310(6990):1315-8.
    doi: 10.1136/bmj.310.6990.1315pmc: PMC2549685pubmed: 7773050google scholar: lookup
  23. Oliver SR. How can health service users contribute to the NHS research and development programme?. BMJ 1995 May 20;310(6990):1318-20.
    doi: 10.1136/bmj.310.6990.1318pmc: PMC2549686pubmed: 7773051google scholar: lookup
  24. Entwistle VA, Renfrew MJ, Yearley S, Forrester J, Lamont T. Lay perspectives: advantages for health research.. BMJ 1998 Feb 7;316(7129):463-6.
    doi: 10.1136/bmj.316.7129.463pmc: PMC2665609pubmed: 9492683google scholar: lookup
  25. Petit-Zeman S, Firkins L, Scadding JW. The James Lind Alliance: tackling research mismatches.. Lancet 2010 Aug 28;376(9742):667-9.
    doi: 10.1016/S0140-6736(10)60712-Xpubmed: 20801389google scholar: lookup
  26. jla.nihr.ac.uk/priority-setting-partnerships/ [Internet]. James Lind Alliance: The PSPs; c2017 [cited 2017 May 08] Available from: http://www.jla.nihr.ac.uk/priority-setting-partnerships/.
  27. Elwyn G, Crowe S, Fenton M, Firkins L, Versnel J, Walker S, Cook I, Holgate S, Higgins B, Gelder C. Identifying and prioritizing uncertainties: patient and clinician engagement in the identification of research questions.. J Eval Clin Pract 2010 Jun;16(3):627-31.
    doi: 10.1111/j.1365-2753.2009.01262.xpubmed: 20482747google scholar: lookup
  28. Lophatananon A, Tyndale-Biscoe S, Malcolm E, Rippon HJ, Holmes K, Firkins LA, Fenton M, Crowe S, Stewart-Brown S, Gnanapragasam VJ, Muir KR. The James Lind Alliance approach to priority setting for prostate cancer research: an integrative methodology based on patient and clinician participation.. BJU Int 2011 Oct;108(7):1040-3.
    doi: 10.1111/j.1464-410X.2011.10609.xpubmed: 21914107google scholar: lookup
  29. jla.nihr.ac.uk [internet]. The James Lind Alliance Guidebook; c2016 [cited 2017 May 08]. Available from: www.jla.nihr.ac.uk/jla-guidebook/.
  30. Cowan K. The James Lind alliance: tackling treatment uncertainties together.. J Ambul Care Manage 2010 Jul-Sep;33(3):241-8.
    doi: 10.1097/JAC.0b013e3181e62cdapubmed: 20539151google scholar: lookup
  31. Bowling A, Ebrahim S. Handbook of Health Services Research Methods; Investigation, measurement and analysis. 1st ed. Open University Press; 2005. pp. 1–638.
  32. Dean R. Identification of research priorities of veterinary surgeons and cat owners with regard to the treatment of Chronic Kidney Disease (CKD) in Cats. [Masters Thesis]. University of Oxford; 2014.
  33. Crowe S. James Lind Alliance Priority Setting Partnerships Setting priorities for treatment uncertainties—a review of methods. James Lind Alliance 2009 [cited 2017 Jun 06].
  34. kwiksurveys.com [Internet]. A survey maker, for individuals and teams; c2017 [cited 2017 Nov 12]. Available from: https://kwiksurveys.com/.
  35. talkaboutlaminitis.co.uk [Internet]. Let’s talk about laminitis; c2017 [cited 2017 Nov 20]. Available from: https://www.talkaboutlaminitis.co.uk/careandconnect.
  36. Grindlay DJ, Brennan ML, Dean RS. Searching the veterinary literature: a comparison of the coverage of veterinary journals by nine bibliographic databases.. J Vet Med Educ 2012 Winter;39(4):404-12.
    pubmed: 23187034doi: 10.3138/jvme.1111.109rgoogle scholar: lookup
  37. Potter M, Gordon S, Hamer P. The Nominal Group Technique: A useful consensus methodology in physiotherapy research. New Zeal J Physiother 2004; 32: 126–130.
  38. Augustana.ca [internet] Random Number Genorator; c2004 [cited 2017 Dec 01]. Available from: http://www.augustana.ca/~mohrj/algorithms/randpick.html.
  39. Eleftheriadou V, Whitton ME, Gawkrodger DJ, Batchelor J, Corne J, Lamb B, Ersser S, Ravenscroft J, Thomas KS. Future research into the treatment of vitiligo: where should our priorities lie? Results of the vitiligo priority setting partnership.. Br J Dermatol 2011 Mar;164(3):530-6.
    doi: 10.1111/j.1365-2133.2010.10160.xpmc: PMC3084501pubmed: 21128908google scholar: lookup
  40. Gadsby R, Snow R, Daly AC, Crowe S, Matyka K, Hall B, Petrie J. Setting research priorities for Type 1 diabetes.. Diabet Med 2012 Oct;29(10):1321-6.
    doi: 10.1111/j.1464-5491.2012.03755.xpubmed: 22823450google scholar: lookup
  41. Ireland JL, Clegg PD, McGowan CM, McKane SA, Pinchbeck GL. A cross-sectional study of geriatric horses in the United Kingdom. Part 1: Demographics and management practices.. Equine Vet J 2011 Jan;43(1):30-6.
    doi: 10.1111/j.2042-3306.2010.00145.xpubmed: 21143631google scholar: lookup
  42. Hotchkiss JW, Reid SW, Christley RM. A survey of horse owners in Great Britain regarding horses in their care. Part 1: Horse demographic characteristics and management.. Equine Vet J 2007 Jul;39(4):294-300.
    doi: 10.2746/042516407x177538pubmed: 17722719google scholar: lookup
  43. cebm.net [internet] Oxford Centre for Evidence-based Medicine–CEBM Levels of Evidence; c2009 [cited 2017 Oct 02]. Available from: https://www.cebm.net/2016/05/ocebm-levels-of-evidence/.
  44. Marr CM, Mair TS. EVE and EVJ online collection of equine endocrinology: recent and future directions; a great start, but still a long way to go.. Equine Vet J 2014 Jan;46(1):97-8.
    doi: 10.1111/evj.12217pubmed: 24329585google scholar: lookup
  45. Finer S, Robb P, Cowan K, Daly A, Robertson E, Farmer A. Top ten research priorities for type 2 diabetes: results from the Diabetes UK-James Lind Alliance Priority Setting Partnership.. Lancet Diabetes Endocrinol 2017 Dec;5(12):935-936.
    doi: 10.1016/S2213-8587(17)30324-8pubmed: 29092776google scholar: lookup
  46. Bang D, Frith CD. Making better decisions in groups.. R Soc Open Sci 2017 Aug;4(8):170193.
    doi: 10.1098/rsos.170193pmc: PMC5579088pubmed: 28878973google scholar: lookup
  47. van der Kolk JH. Equine Cushing’s disease. Equine Vet Edu 1997; 9(2): 209–214.
  48. Beech J. Treatment of hypophysial adenomas. Compend Contin Educ 1994; 16: 921–923.
  49. Donaldson MT, LaMonte BH, Morresey P, Smith G, Beech J. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease).. J Vet Intern Med 2002 Nov-Dec;16(6):742-6.
    doi: 10.1892/0891-6640(2002)016<0742:twpoco>2.3.co;2pubmed: 12465775google scholar: lookup
  50. Perkins GA, Lamb S, Erb HN, Schanbacher B, Nydam DV, Divers TJ. Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide.. Equine Vet J 2002 Nov;34(7):679-85.
    doi: 10.2746/042516402776250333pubmed: 12455838google scholar: lookup
  51. Schott II HC, Rapson JR, Marteniuk J V, Wismer S. Long-term response of equids with pituitary pars intermedia dysfunction to treatment with pergolide. Proc 60th Annu Conv Am Assoc Equine Pract Salt Lake City, Utah, USA, December 6–10 2014 2014;329.
  52. Horn R, Bamford NJ, Afonso T, Sutherland M, Buckerfield J, Tan RHH, Secombe CJ, Stewart AJ, Bertin FR. Factors associated with survival, laminitis and insulin dysregulation in horses diagnosed with equine pituitary pars intermedia dysfunction.. Equine Vet J 2019 Jul;51(4):440-445.
    doi: 10.1111/evj.13041pubmed: 30417404google scholar: lookup
  53. Couëtil L, Paradis MR, Knoll J. Plasma adrenocorticotropin concentration in healthy horses and in horses with clinical signs of hyperadrenocorticism.. J Vet Intern Med 1996 Jan-Feb;10(1):1-6.
    doi: 10.1111/j.1939-1676.1996.tb02016.xpubmed: 8965262google scholar: lookup
  54. Beech J, Boston R, Lindborg S, Russell GE. Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia.. J Am Vet Med Assoc 2007 Aug 1;231(3):417-26.
    doi: 10.2460/javma.231.3.417pubmed: 17669045google scholar: lookup
  55. Horowitz ML, Neal L, Watson JL. Characteristics of plasma adrenocorticotropin, β‐endorphin and α‐melanocyte stimulating hormone as diagnostic tests for pituitary pars intermedia dysfunction in the horse. J Vet Intern Med 2003; 17, 386.
  56. Fazio E, Medica P, Aronica V, Grasso L, Ferlazzo A. Circulating beta-endorphin, adrenocorticotrophic hormone and cortisol levels of stallions before and after short road transport: stress effect of different distances.. Acta Vet Scand 2008 Mar 3;50(1):6.
    pmc: PMC2268694pubmed: 18315878doi: 10.1186/1751-0147-50-6google scholar: lookup
  57. Ayala I, Martos NF, Silvan G, Gutierrez-Panizo C, Clavel JG, Illera JC. Cortisol, adrenocorticotropic hormone, serotonin, adrenaline and noradrenaline serum concentrations in relation to disease and stress in the horse.. Res Vet Sci 2012 Aug;93(1):103-7.
    doi: 10.1016/j.rvsc.2011.05.013pubmed: 21641009google scholar: lookup
  58. Stewart AJ, Hackett E, Bertin FR, Towns TJ. Cortisol and adrenocorticotropic hormone concentrations in horses with systemic inflammatory response syndrome.. J Vet Intern Med 2019 Sep;33(5):2257-2266.
    doi: 10.1111/jvim.15620pmc: PMC6766528pubmed: 31512777google scholar: lookup
  59. Morris C, Simkiss D, Busk M, Morris M, Allard A, Denness J, Janssens A, Stimson A, Coghill J, Robinson K, Fenton M, Cowan K. Setting research priorities to improve the health of children and young people with neurodisability: a British Academy of Childhood Disability-James Lind Alliance Research Priority Setting Partnership.. BMJ Open 2015 Jan 28;5(1):e006233.
    doi: 10.1136/bmjopen-2014-006233pmc: PMC4316435pubmed: 25631309google scholar: lookup

Citations

This article has been cited 4 times.
  1. Kirkwood NC, Hughes KJ, Stewart AJ. Pituitary Pars Intermedia Dysfunction (PPID) in Horses. Vet Sci 2022 Oct 10;9(10).
    doi: 10.3390/vetsci9100556pubmed: 36288169google scholar: lookup
  2. Collinson A, Brennan ML, Dean RS, Stavisky J. Priorities for Research into the Impact of Canine Surgical Sterilisation Programmes for Free-Roaming Dogs: An International Priority Setting Partnership. Animals (Basel) 2021 Jul 30;11(8).
    doi: 10.3390/ani11082250pubmed: 34438707google scholar: lookup
  3. Page AE, Johnson M, Parker JL, Jacob O, Poston R, Adams AA, Adam EN. The Effects of Intra-Articular Triamcinolone and Autologous Protein Solution on Metabolic Parameters in Horses. Animals (Basel) 2024 Aug 2;14(15).
    doi: 10.3390/ani14152250pubmed: 39123776google scholar: lookup
  4. Amenu K, McIntyre KM, Moje N, Knight-Jones T, Rushton J, Grace D. Approaches for disease prioritization and decision-making in animal health, 2000-2021: a structured scoping review. Front Vet Sci 2023;10:1231711.
    doi: 10.3389/fvets.2023.1231711pubmed: 37876628google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.